Tagged with M

Turkey Hande Demirdere, general manager of Pierre Fabre Pharma in Turkey, sheds light on the affiliate’s impressive 93 percent growth in 2017 while highlighting where to target development opportunities in the dynamic Turkish market. In this interview, the experienced General Manager discusses the advantages of diversifying strategies, Pierre Fabre’s comparative advantage…

China Xie Yuehui, chairman and CEO of Lifetech Scientific, one of Shenzhen’s leading medical devices companies, share the company’s focus on developing innovative minimally invasive interventional medical devices to global standards, the company’s strengths in commercialization, as well as his strategic plans for the future.   Mr. Xie, could you please…

Turkey Selim Giray, the recently appointed VP and general manager of GSK Turkey, provides insights into the company’s eye-catching footprint and commitment to Turkey, his ambition to integrate into the market’s Top Four ranking in the coming years, as well as his aspirations to see the industry and the government work…

UK Professor David Garway-Heath, a specialist in glaucoma, talks with us about the screening devices of the future, low awareness of glaucoma as a chronic disease and collaboration in training and establishing standards of care on a European level.   I see technology as the enabler that creates new possibilities. Imaging…

Turkey In Summer 2018, we spoke to Adriano Antonio Treve, then general manager of Roche Turkey, now Area Head Central Eastern Europe, Turkey, Russia, Central Asia, Iran, Pakistan & Indian Subcontinent. Treve provided insights into the main opportunities and challenges of the Turkish market, Roche’s unrivalled commitment to making a difference…

China Dr. Harley Seyedin, president of AmCham South China, talks up increasing connectivity in the region, competition and collaboration between the Greater Bay Area cities, and their potential for international life sciences investors. Harley, you have been in the South China region as an extremely successful businessman for nearly three decades.…

Turkey Elif Aral, country manager of Pfizer Turkey, stresses that Turkey will continue to be perceived as essential and important, where healthcare is a top priority with its young but aging population. In addition, as the newly appointed Chairman of the Board of Directors of the Association of Research-Based Pharmaceutical Companies…

UK Karen Osborn, CEO of the International Glaucoma Association, explains the role of the charity, detailing its threefold purpose of funding research, raising awareness and helping patients live with the disease. She speaks about possible care pathways of the future and international collaboration on research.   We also collaborate on workshops…

Metos Rupert Mok, a veteran of the Hong Kong medtech industry, discusses regulatory alignment between Hong Kong and mainland China, opportunities for collaboration, the consumer ‘wearable’ space, and the state of the territory’s start-up ecosystem.   Having worked in the Hong Kong medical device and equipment industry for three decades now,…

UK After spending five years heading market access globally, Lars Bruening returned to a country manager role in the UK; he shares with us his thoughts on Brexit while also highlighting exciting Phase III developments and introducing the new Baylab opened by Bayer in Reading (near London).   It is this…

Turkey Abdi İbrahim Otsuka, the Turkish-Japanese hybrid pharmaceutical company, celebrated their five-year anniversary just last year and have ambitions to become the Number One Japanese company in Turkey. Elif Elkin, in her second general manager position, sets out her priorities, comments on the marriage of Turkish and Japanese work practices, and…

Hong Kong Ingrid Reinli, general manager of the European Chamber of Commerce in Hong Kong, discusses the chamber´s strategic priorities and how it serves to unify the European presence in the market. She also reflects on the relationship between Hong Kong and the many European countries investing into the region. Why did…